Expert Insight on Important Clinical Trial Data From ESMO 2021 Informing Treatment for Endometrial and Ovarian Cancer

In this episode, Prof. Isabelle Ray-Coquard, MD, PhD, and Bernard Doger de Spéville, MD, PhD, provide expert insights on key new data from ESMO 2021 presented for endometrial and ovarian cancers including:

• Data from the phase III OReO/ENGOT Ov-38 trial of olaparib rechallenge in patients with recurrent ovarian cancer previously treated with a PARP inhibitor  
• A subgroup analysis of KEYNOTE-775, comparing lenvatinib vs pembrolizumab vs TPC, with outcomes by tumor histology and prior lines of therapy
• A preplanned analysis from phase III NRG-GY004 of outcomes by HRD status for olaparib with or without cediranib vs platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancer
• Quality-adjusted time without symptom or toxicity from the phase III PRIMA trial of maintenance niraparib vs placebo in newly diagnosed advanced ovarian cancer

Presenters:

Prof. Isabelle Ray-Coquard, MD, PhD
Professor of Department of Medical Oncology
Clinical Science Institute of the Léon Bérard Center
Lyon, France

Bernard Doger de Spéville, MD, PhD
Medical Oncologist
START-Madrid, Early Phase Clinical Trials Unit
Hospital Fundación Jiménez Díaz
Madrid, Spain

Content supported by an educational grant from GlaxoSmithKline.

Link to full program, including a downloadable highlights slideset and ClinicalThought commentaries:
https://bit.ly/3dAttwi